|
US4714681A
(en)
|
1981-07-01 |
1987-12-22 |
The Board Of Reagents, The University Of Texas System Cancer Center |
Quadroma cells and trioma cells and methods for the production of same
|
|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
AU584417B2
(en)
|
1985-04-01 |
1989-05-25 |
Lonza Group Ag |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US5589173A
(en)
|
1986-11-04 |
1996-12-31 |
Genentech, Inc. |
Method and therapeutic compositions for the treatment of myocardial infarction
|
|
US5223427A
(en)
|
1987-03-31 |
1993-06-29 |
The Scripps Research Institute |
Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
|
|
US5437864A
(en)
|
1987-03-31 |
1995-08-01 |
The Scripps Research Institute |
Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
|
|
US5750172A
(en)
|
1987-06-23 |
1998-05-12 |
Pharming B.V. |
Transgenic non human mammal milk
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
US5879936A
(en)
|
1988-04-18 |
1999-03-09 |
Aluguisse Holding A.G. |
Recombinant DNA methods, vectors and host cells
|
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
|
WO1989011297A1
(en)
|
1988-05-27 |
1989-11-30 |
Centocor, Inc. |
Freeze-dried formulation for antibody products
|
|
EP0420937B1
(en)
|
1988-06-21 |
1994-11-09 |
Genentech, Inc. |
Therapeutic compositions for the treatment of myocardial infarction
|
|
US4925648A
(en)
|
1988-07-29 |
1990-05-15 |
Immunomedics, Inc. |
Detection and treatment of infectious and inflammatory lesions
|
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
ES2096590T3
(es)
|
1989-06-29 |
1997-03-16 |
Medarex Inc |
Reactivos biespecificos para la terapia del sida.
|
|
US5633076A
(en)
|
1989-12-01 |
1997-05-27 |
Pharming Bv |
Method of producing a transgenic bovine or transgenic bovine embryo
|
|
US5891693A
(en)
|
1990-01-25 |
1999-04-06 |
Alusuisse Holdings A.G. |
Recombinant DNA methods vectors and host cells
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
AU667460B2
(en)
|
1990-10-05 |
1996-03-28 |
Medarex, Inc. |
Targeted immunostimulation with bispecific reagents
|
|
US5506134A
(en)
|
1990-10-22 |
1996-04-09 |
Corvas International, Inc. |
Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
|
|
EP0557300B1
(en)
|
1990-10-29 |
1997-11-19 |
Chiron Corporation |
Bispecific antibodies, method of production, and uses thereof
|
|
JP3149960B2
(ja)
|
1991-01-24 |
2001-03-26 |
財団法人化学及血清療法研究所 |
ヒト組織因子を定量する方法
|
|
IE921342A1
(en)
|
1991-04-26 |
1992-11-04 |
Surface Active Ltd |
Novel antibodies, and methods for their use
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
AU2235992A
(en)
|
1991-06-14 |
1993-01-12 |
Genpharm International, Inc. |
Transgenic immunodeficient non-human animals
|
|
DE69224906T2
(de)
|
1991-07-08 |
1998-10-29 |
Univ Massachusetts |
Thermotropes flüssig-kristallines segment-blockcopolymer
|
|
US5525497A
(en)
|
1991-11-27 |
1996-06-11 |
Keller; Walter |
Recombinant poly(A) polymerase
|
|
CA2124967C
(en)
|
1991-12-17 |
2008-04-08 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
JPH05244988A
(ja)
|
1992-03-04 |
1993-09-24 |
Green Cross Corp:The |
抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤
|
|
EP1306095A3
(en)
|
1992-03-05 |
2003-06-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
WO1994005328A1
(en)
|
1992-08-28 |
1994-03-17 |
The Scripps Research Institute |
Inhibition of tumor metastasis via neutralization of tissue factor function
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5879677A
(en)
|
1992-12-09 |
1999-03-09 |
The Scripps Research Institute |
Method for inhibition of cerebral tissue factor mediated reperfusion damage
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
DE69424687T2
(de)
|
1993-03-09 |
2000-09-07 |
Genzyme Corp., Cambridge |
Verfahren zur isolierung von proteinen aus milch
|
|
CA2161351C
(en)
|
1993-04-26 |
2010-12-21 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
AU702250B2
(en)
|
1994-07-11 |
1999-02-18 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the specific coagulation of vasculature
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
PT833911E
(pt)
|
1995-06-07 |
2004-09-30 |
Ortho Mcneil Pharm Inc |
Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
|
|
CA2226575C
(en)
|
1995-07-27 |
2011-10-18 |
Genentech, Inc. |
Stabile isotonic lyophilized protein formulation
|
|
JPH09302000A
(ja)
|
1996-05-16 |
1997-11-25 |
Chemo Sero Therapeut Res Inst |
抗組織因子モノクローナル抗体及び当該モノクローナル抗体を用いた組織因子凝固活性の測定法
|
|
US6593291B1
(en)
|
1997-02-06 |
2003-07-15 |
Entremed, Inc. |
Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
|
|
US5986065A
(en)
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
US7749498B2
(en)
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
US20040229282A1
(en)
|
1997-03-10 |
2004-11-18 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
EP0999853B1
(en)
|
1997-06-13 |
2003-01-02 |
Genentech, Inc. |
Stabilized antibody formulation
|
|
US6677436B1
(en)
|
1998-04-03 |
2004-01-13 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
|
|
DE60037896D1
(de)
|
1999-07-29 |
2008-03-13 |
Medarex Inc |
Menschliche antikörper gegen her2/neu
|
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
|
JP2001213804A
(ja)
|
2000-01-31 |
2001-08-07 |
Chugai Pharmaceut Co Ltd |
抗組織因子抗体の複合体
|
|
EP1263960A2
(en)
|
2000-03-16 |
2002-12-11 |
Genentech, Inc. |
Anti-tissue factor antibodies with enhanced anticoagulant potency
|
|
US7329745B2
(en)
|
2000-06-13 |
2008-02-12 |
City Of Hope |
Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
|
|
WO2002011753A1
(en)
|
2000-08-04 |
2002-02-14 |
Chugai Seiyaku Kabushiki Kaisha |
Protein injection preparations
|
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
CN1487996B
(zh)
|
2000-11-30 |
2010-06-16 |
米德列斯公司 |
用于生产人类抗体的转基因转染色体啮齿动物
|
|
EP1374896A4
(en)
|
2001-03-26 |
2005-04-06 |
Koji Suzuki |
MEANS TO IMPROVE THE FLUID CHARACTERISTICS OF BLOOD
|
|
US6605478B2
(en)
|
2001-03-30 |
2003-08-12 |
Appleid Materials, Inc, |
Kill index analysis for automatic defect classification in semiconductor wafers
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
AU2002256895B2
(en)
|
2001-05-18 |
2008-09-18 |
Kirin Beer Kabushiki Kaisha |
Anti-TRAIL-R antibodies
|
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
|
CA2454587C
(en)
|
2001-07-25 |
2012-11-13 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
|
EP1429650B1
(en)
|
2001-08-30 |
2009-06-24 |
Mount Sinai School of Medicine of New York University |
Alternatively spliced circulating tissue factor
|
|
WO2003026577A2
(en)
|
2001-09-24 |
2003-04-03 |
Seattle Genetics, Inc. |
P-amidobenzylethers in drug delivery agents
|
|
EP1434802A1
(en)
|
2001-10-02 |
2004-07-07 |
Novo Nordisk A/S |
Human tissue factor antibodies
|
|
US20050169927A1
(en)
|
2001-10-02 |
2005-08-04 |
Novo Nordisk A/S |
Human tissue factor antibodies
|
|
TWI338009B
(en)
|
2001-10-29 |
2011-03-01 |
Genentech Inc |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
JP2005507008A
(ja)
|
2001-11-02 |
2005-03-10 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
アポトーシスに関連した症状の治療のための、組織因子アゴニストまたは組織因子アンタゴニストの使用
|
|
JP5290489B2
(ja)
|
2001-11-08 |
2013-09-18 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Ｉｇｇ抗体の安定な液体医薬製剤
|
|
US20050096289A1
(en)
|
2002-02-07 |
2005-05-05 |
Hans Prydz |
Methods and compositions for modulating tissue factor
|
|
EP1573002A4
(en)
*
|
2002-02-11 |
2008-07-16 |
Genentech Inc |
ANTIBODY VARIANTS WITH FASTER ANTIGEN ASSOCIATION SPEEDS
|
|
CA2476832A1
(en)
|
2002-02-22 |
2003-08-28 |
Prophy Med Ab |
Use of an inhibitor or antagonist against tissue factor
|
|
US20070148171A1
(en)
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
JP4567437B2
(ja)
|
2002-05-01 |
2010-10-20 |
バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト |
抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質
|
|
WO2004004639A2
(en)
|
2002-07-02 |
2004-01-15 |
Smithkline Beecham Corporation |
A novel stable formulation
|
|
AU2003242506A1
(en)
|
2002-07-12 |
2004-02-02 |
Novo Nordisk A/S |
Tf antagonist
|
|
SI1545613T1
(sl)
|
2002-07-31 |
2011-11-30 |
Seattle Genetics Inc |
Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
US20050106139A1
(en)
|
2002-10-31 |
2005-05-19 |
Ivan Svendsen |
Humanized tissue factor antibodies
|
|
AU2003277832A1
(en)
|
2002-10-31 |
2004-05-25 |
Novo Nordisk A/S |
Humanized tissue factor antibodies
|
|
WO2004041296A2
(en)
|
2002-11-06 |
2004-05-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
|
|
WO2004041302A1
(en)
|
2002-11-06 |
2004-05-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
JP2006516564A
(ja)
|
2003-01-22 |
2006-07-06 |
ノボ ノルディスク アクティーゼルスカブ |
Ｔｆ結合薬剤及びそれらの使用
|
|
RU2358763C2
(ru)
|
2003-02-10 |
2009-06-20 |
Элан Фармасьютикалз, Инк. |
Композиции иммуноглобулина и способ их получения
|
|
US20060034846A1
(en)
|
2003-04-14 |
2006-02-16 |
Mirella Ezban |
Use of TF antagonists
|
|
US7425328B2
(en)
|
2003-04-22 |
2008-09-16 |
Purdue Pharma L.P. |
Tissue factor antibodies and uses thereof
|
|
AU2004251161A1
(en)
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
|
US7605235B2
(en)
|
2003-05-30 |
2009-10-20 |
Centocor, Inc. |
Anti-tissue factor antibodies and compositions
|
|
KR20060035608A
(ko)
|
2003-05-30 |
2006-04-26 |
센토코 인코포레이티드 |
항 조직 인자 항체로 종양 성장을 저해하는 방법
|
|
MXPA05012723A
(es)
*
|
2003-05-30 |
2006-02-08 |
Genentech Inc |
Tratamiento con anticuerpos anti-vgf.
|
|
AU2004255553B2
(en)
|
2003-06-19 |
2009-08-20 |
Genentech, Inc. |
Compositions and methods for treating coagulation related disorders
|
|
CA2531684C
(en)
|
2003-07-22 |
2014-03-11 |
Crucell Holland B.V. |
Binding molecules against sars-coronavirus and uses thereof
|
|
WO2005025623A2
(en)
|
2003-07-28 |
2005-03-24 |
Emory University |
Ef-24-factor vii conjugates
|
|
US20050028649A1
(en)
|
2003-08-06 |
2005-02-10 |
Dan Settanni |
Box wrench with hinged socket
|
|
WO2005020927A2
(en)
|
2003-08-29 |
2005-03-10 |
Centocor, Inc. |
Method of promoting graft survival with anti-tissue factor antibodies
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
RS53984B1
(sr)
|
2003-12-10 |
2015-10-30 |
E. R. Squibb & Sons L.L.C. |
Ip-10 antitela i njihove upotrebe
|
|
NZ547157A
(en)
|
2003-12-10 |
2009-07-31 |
Medarex Inc |
Interferon Alpha Antibodies and their uses
|
|
WO2005079766A2
(en)
|
2004-02-20 |
2005-09-01 |
Novo Nordisk A/S |
Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
|
|
EP1718667B1
(en)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
AU2005218642B2
(en)
|
2004-03-02 |
2011-04-28 |
Seagen Inc. |
Partially loaded antibodies and methods of their conjugation
|
|
WO2005118646A2
(en)
|
2004-04-26 |
2005-12-15 |
Centocor, Inc. |
Epitope directed selection of antibodies to murine tissue factor
|
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
|
KR20070036130A
(ko)
|
2004-07-16 |
2007-04-02 |
화이자 프로덕츠 인코포레이티드 |
항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
|
|
US20070196364A1
(en)
|
2004-07-27 |
2007-08-23 |
Human Genome Sciences, Inc. |
Pharmaceutical Formulation and Process
|
|
WO2006014965A2
(en)
|
2004-07-27 |
2006-02-09 |
Human Genome Sciences, Inc. |
Pharmaceutical formulation and process
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
WO2006132670A2
(en)
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the n terminus
|
|
EP1817341A2
(en)
|
2004-11-29 |
2007-08-15 |
Seattle Genetics, Inc. |
Engineered antibodies and immunoconjugates
|
|
EP1676574A3
(en)
|
2004-12-30 |
2006-07-26 |
Johnson & Johnson Vision Care, Inc. |
Methods for promoting survival of transplanted tissues and cells
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
DK1888113T3
(da)
|
2005-05-27 |
2014-09-01 |
Biogen Idec Inc |
Tweak-bindende antistoffer
|
|
EP1898529A1
(en)
|
2005-06-28 |
2008-03-12 |
Pioneer Corporation |
Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
|
|
WO2007008600A2
(en)
|
2005-07-07 |
2007-01-18 |
Nellix, Inc. |
Systems and methods for endovascular aneurysm treatment
|
|
HUE035853T2
(en)
|
2005-07-18 |
2018-05-28 |
Seattle Genetics Inc |
Beta-glucuronide-linker-drug conjugates
|
|
CA2615374A1
(en)
|
2005-07-18 |
2007-01-25 |
Ernest Kun Kun |
Treatment of cancer
|
|
WO2007019232A2
(en)
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
CN101237881B
(zh)
|
2005-08-03 |
2015-04-22 |
伊缪诺金公司 |
免疫偶联物剂型
|
|
US20090214563A1
(en)
|
2005-10-21 |
2009-08-27 |
Genentech, Inc. |
Treatment for antiphospholipid-syndrome-related pregnancy complications
|
|
BRPI0618338A2
(pt)
|
2005-11-07 |
2011-08-23 |
Scripps Resarch Inst |
uso de inibidor de sinalização de fator tecidual, método para identificar um agente que inibe a sinalização de tf/viia, composições farmacêuticas e kit
|
|
WO2007058935A2
(en)
|
2005-11-14 |
2007-05-24 |
Bausch & Lomb Incorporated |
Ophthalmic composition for dry eye therapy
|
|
US10155816B2
(en)
|
2005-11-28 |
2018-12-18 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
WO2008030260A2
(en)
|
2005-12-22 |
2008-03-13 |
Genentech, Inc. |
Treatment of variola viral infections using a tissue factor inhibitor
|
|
JP2007196364A
(ja)
|
2005-12-28 |
2007-08-09 |
Sumitomo Electric Ind Ltd |
表面被覆切削工具およびその製造方法
|
|
EP2066353B1
(en)
*
|
2006-09-29 |
2013-01-02 |
AstraZeneca AB |
Combination of zd6474 and bevacizumab for cancer therapy
|
|
KR20140116546A
(ko)
|
2006-10-27 |
2014-10-02 |
제넨테크, 인크. |
항체 및 면역접합체 및 이들의 용도
|
|
NO347649B1
(no)
|
2006-12-14 |
2024-02-12 |
Regeneron Pharma |
Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
|
|
AR065271A1
(es)
|
2007-02-09 |
2009-05-27 |
Genentech Inc |
Anticuerpos anti-robo4 y sus usos
|
|
US20080311034A1
(en)
|
2007-04-30 |
2008-12-18 |
Anderson Glenn M |
Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
CA2686225A1
(en)
|
2007-06-22 |
2008-12-31 |
Scidose Llc |
Solubilized formulation of docetaxel without tween 80
|
|
WO2009097006A2
(en)
|
2007-08-10 |
2009-08-06 |
Medarex, Inc. |
Hco32 and hco27 and related examples
|
|
CN101969970B
(zh)
|
2007-10-12 |
2014-10-15 |
西雅图基因公司 |
用抗体-药物偶联物联合治疗
|
|
JP4824710B2
(ja)
|
2008-02-08 |
2011-11-30 |
国立清華大学 |
グラフト共重合体およびブロック共重合体の多機能混合ミセルならびにその製造方法
|
|
AU2009316592B2
(en)
|
2008-11-20 |
2016-01-07 |
Genentech, Inc. |
Therapeutic protein formulations
|
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
|
CA3159253A1
(en)
|
2009-01-09 |
2010-07-15 |
Seagen Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
|
EP3511342B1
(en)
|
2010-03-10 |
2024-01-17 |
Genmab A/S |
Monoclonal antibodies against c-met
|
|
CN104998269B
(zh)
|
2010-03-22 |
2019-06-11 |
弗·哈夫曼-拉罗切有限公司 |
对于稳定含有蛋白质的制剂有用的组合物和方法
|
|
JP6055404B2
(ja)
|
2010-06-15 |
2016-12-27 |
ゲンマブ エー／エス |
組織因子に対するヒト抗体薬物結合体
|
|
US20160120976A1
(en)
|
2010-08-18 |
2016-05-05 |
Immunomedics, Inc. |
Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
|
|
ES2676205T3
(es)
|
2011-03-31 |
2018-07-17 |
Merck Sharp & Dohme Corp. |
Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
|
|
JP6238459B2
(ja)
|
2011-08-01 |
2017-11-29 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
|
|
KR102557309B1
(ko)
|
2012-05-15 |
2023-07-20 |
씨젠 인크. |
자가-안정화 링커 접합체
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
US10131712B2
(en)
|
2012-08-14 |
2018-11-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
MX379066B
(es)
|
2012-09-18 |
2025-03-04 |
Taris Biomedical Llc |
Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior.
|
|
PL2991683T3
(pl)
|
2013-05-02 |
2020-03-31 |
Glykos Finland Oy |
Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
KR102372245B1
(ko)
|
2013-11-21 |
2022-03-08 |
젠맵 에이/에스 |
항체-약물 접합체 동결건조 제제
|
|
EP3074423A1
(en)
|
2013-11-25 |
2016-10-05 |
Oxford BioTherapeutics Ltd |
Antibodies anti matriptase for the treatment of cancer
|
|
WO2015088847A1
(en)
|
2013-12-11 |
2015-06-18 |
Glaxosmithkline Llc |
Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
|
|
MY184154A
(en)
|
2013-12-12 |
2021-03-23 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
CA2942039A1
(en)
|
2014-02-18 |
2015-08-27 |
Health Research, Inc. |
Combination therapy for hepatocellular carcinoma
|
|
ES2895623T3
(es)
|
2014-05-22 |
2022-02-22 |
Byondis Bv |
Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
CN105330740B
(zh)
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
|
CA2955676A1
(en)
|
2014-08-25 |
2016-03-03 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
|
BR112017010788A2
(pt)
*
|
2014-12-23 |
2017-12-26 |
Genentech Inc |
métodos de identificação de um paciente com câncer e de identificação de um paciente que sofre de câncer que pode beneficiar da administração de um antagonista de vegf, método de tratamento de um paciente com câncer e método para determinar o estágio de câncer de ovário
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
KR102055396B1
(ko)
|
2015-08-11 |
2019-12-12 |
우시 바이올로직스 (케이만) 인코포레이티드 |
신규한 항-pd-1 항체
|
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
HUE055109T2
(hu)
*
|
2015-09-11 |
2021-11-29 |
Genmab As |
Adagolási rendek TF elleni antitest és gyógyszer konjugátumaihoz
|
|
PL3368572T3
(pl)
|
2015-10-02 |
2022-09-12 |
Symphogen A/S |
Przeciwciała anty-PD-1 oraz kompozycje
|
|
CN106632674B
(zh)
|
2015-10-30 |
2018-11-16 |
泽达生物医药有限公司 |
一种抗pd-1单克隆抗体、其药物组合物及其用途
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
US20170181988A1
(en)
|
2015-12-23 |
2017-06-29 |
Cipla Limited |
Methods for the treatment of bladder cancer
|
|
ES2875747T3
(es)
*
|
2016-01-11 |
2021-11-11 |
Univ Leland Stanford Junior |
Proteínas quiméricas y métodos de inmunoterapia
|
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
US10613092B2
(en)
|
2016-04-01 |
2020-04-07 |
Agilent Technologies, Inc. |
Scoring methods for anti-PD therapy eligibility and compositions for performing same
|
|
CN107286242B
(zh)
|
2016-04-01 |
2019-03-22 |
中山康方生物医药有限公司 |
抗pd-1的单克隆抗体
|
|
AU2017266298B2
(en)
|
2016-05-18 |
2024-01-04 |
Boehringer Ingelheim International Gmbh |
Anti PD-1 and anti-LAG3 antibodies for cancer treatment
|
|
US11299543B2
(en)
|
2016-06-02 |
2022-04-12 |
Bristol-Myers Squibb Company |
Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
CN106938051B
(zh)
|
2016-08-22 |
2019-10-11 |
复旦大学 |
靶向于组织因子的抗体-药物偶联物
|
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
|
CN107840887B
(zh)
|
2016-09-21 |
2022-03-25 |
基石药业（苏州）有限公司 |
一种新的pd-1单克隆抗体
|
|
CN107077506A
(zh)
|
2016-12-07 |
2017-08-18 |
深圳市大疆创新科技有限公司 |
无人机的控制方法及无人机
|
|
IL274122B2
(en)
*
|
2017-11-02 |
2024-09-01 |
Genmab As |
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
|
EP3735271A4
(en)
|
2018-01-04 |
2022-06-15 |
Iconic Therapeutics, Inc. |
ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
|
|
CN112105388A
(zh)
|
2018-03-07 |
2020-12-18 |
展马博联合股份有限公司 |
抗组织因子抗体-药物偶联物及其在癌症治疗中的应用
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
JP6833756B2
(ja)
|
2018-04-13 |
2021-02-24 |
日本電信電話株式会社 |
光演算素子と多層ニューラルネットワーク
|
|
WO2019217455A1
(en)
|
2018-05-07 |
2019-11-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
WO2019217457A1
(en)
|
2018-05-07 |
2019-11-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
AU2019321442A1
(en)
|
2018-08-16 |
2021-02-11 |
Genmab A/S |
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
|
|
KR20220093344A
(ko)
|
2019-11-07 |
2022-07-05 |
도쿄엘렉트론가부시키가이샤 |
기판 처리 장치, 기판 처리 방법 및 기억 매체
|
|
MX2022005222A
(es)
|
2019-11-07 |
2022-06-08 |
Genmab As |
Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
|
|
MX2022015375A
(es)
|
2020-06-29 |
2023-01-16 |
Genmab As |
Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
|